These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8459265)

  • 1. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.
    Martoni A; Panetta A; Angelelli B; Melotti B; Pannuti F
    J Chemother; 1993 Feb; 5(1):47-51. PubMed ID: 8459265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
    Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
    Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of carboplatin and cisplatin in advanced ovarian cancer.
    Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M
    Eur J Gynaecol Oncol; 1994; 15(4):277-82. PubMed ID: 7957335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer.
    Teeling M; Carney DN
    Eur J Gynaecol Oncol; 1990; 11(3):219-24. PubMed ID: 2209642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee.
    Swenerton KD; Pater JL
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):114-9. PubMed ID: 1411622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Pavlidis N; Gennatas K; Beer M; Mylonakis N; Makrantonakis P; Klouvas G; Karpathios S; Linardou H; Konstantaras C; Fountzilas G
    Eur J Cancer; 1996 Mar; 32A(3):421-8. PubMed ID: 8814685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ
    J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study.
    Zamagni C; Martoni A; Cacciari N; Gentile A; Pannuti F
    Am J Clin Oncol; 1998 Oct; 21(5):491-7. PubMed ID: 9781607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer.
    Smith HO; Goldberg GL; Carol L; Davidson SA; Tomaino C; Centrilla L; Runowicz CD
    Eur J Gynaecol Oncol; 1994; 15(6):411-7. PubMed ID: 7875155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.